Cancers, Vol. 12, Pages 2636: Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical Trials

Cancers, Vol. 12, Pages 2636: Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical Trials Cancers doi: 10.3390/cancers12092636 Authors: Timothy A. Lin Clifton David Fuller Vivek Verma Walker Mainwaring Andres F. Espinoza Austin B. Miller Amit Jethanandani Dario Pasalic Prajnan Das Bruce D. Minsky Charles R. Thomas David R. Fogelman Vivek Subbiah Ishwaria M. Subbiah Ethan B. Ludmir The pace of clinical trial data generation and publication is an area of interest within clinical oncology; however, little is known about the dynamics and covariates of time to reporting (TTR) of trial results. To assess these, ClinicalTrials.gov was queried for phase three clinical trials for patients with metastatic solid tumors, and the factors associated with TTR from enrollment completion to publication were analyzed. Based on the 319 included trials, cooperative-group-sponsored trials were reported at a slower rate than non-cooperative-group trials (median 37.5 vs. 31.0 months; p < 0.001), while industry-funded studies were reported at a faster rate than non-industry-supported trials (31.0 vs. 40.0 months; p = 0.005). Furthermore, successful trials (those meeting their primary endpoint) were reported at a faster rate than unsuccessful studies (27.5 vs. 36.0 months; p < 0.001). Multivariable analysis confirmed that industry funding was independently associated with a shorter TTR (p = 0.006), while cooperative g...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Brief Report Source Type: research